RankAlpha logo
Back to Rankings

HALO

Halozyme TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The earnings follow-up supports a still-positive post-print read: Halozyme beat the Zacks-tracked Q1 EPS and revenue figures cited by AP, reiterated full-year guidance, and paired that with a larger buyback, which together argue that royalty growth and margin conversion remain intact.
Posture
Constructive
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Forward growth still relies on development-stage programs converting into approvals and commercial uptake over several years, so timeline slips can defer the next royalty wave.
Momentum
47
Value
67
Sentiment
65
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $79.00 · Bull $88.00 · Bear $60.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $84.50
Why
Momentum47 · Δ7d +2.3
Value67 · Δ7d +0.3
Sentiment65 · Δ7d +3.6
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
47
34% active weight
Current posture
7d trendImproving
Δ7d
+2.3
Δ21d
+26.7
Value
67
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.8
Sentiment
65
33% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+2.7
Why this grade

Composite grade B. Momentum 46.5 / Value 66.8 / Sentiment 64.9

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$8.08B
Beta
0.97
Shares Out
117.6M
P/E (TTM)
15.0
P/S (TTM)
6.74
P/FCF (TTM)
13.90
Rev YoY
+22.1%
EPS YoY
+36.0%
Gross Margin
+84.5%
Op Margin
+59.3%
Net Debt
$909.72M
Current Ratio
1.59
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology